Stocks › OCGN

Ocugen, Inc.

OCGN·Nasdaq·United States United States·USD
$0.77
+0.04 (+4.79%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
OCGN
Ocugen, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
OCGNS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of OCGN by members of U.S. Congress · 2 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Christopher L. JacobsChristopher L. JacobsHouse · R · NY OCGNOcugen, Inc. · Stock Sale
$1,001 - $15,000
Dec 12, 2022 Nov 8, 2022 Filing ↗
Christopher L. JacobsChristopher L. JacobsHouse · R · NY OCGNOcugen, Inc. · Stock Purchase
$15,001 - $50,000
Jul 28, 2022 Jun 16, 2022 Filing ↗

Whale Activity

Position changes in OCGN reported for 2026-09-30 by 168 institutional filers
Increased: 44New: 20Held: 41Decreased: 37Closed: 20No prior filing: 6
  • Increased44
  • New20
  • Held41
  • Decreased37
  • Closed20
  • No prior filing6
FilerSharesValueChange
BlackRock, Inc.27.8M$28.6Mincreased
STATE STREET CORP19.5M$20.1Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC14.1M$14.6Mdecreased
MILLENNIUM MANAGEMENT LLC12.2M$12.5Mdecreased
UBS Group AG9.6M$9.8Mincreased
GEODE CAPITAL MANAGEMENT, LLC8.7M$8.9Mdecreased
RTW INVESTMENTS, LP6.7M$6.9Mheld
TWO SIGMA INVESTMENTS, LP3.9M$4.1Mincreased
Ikarian Capital, LLC3.6M$3.7Mdecreased
GMT CAPITAL CORP3.5M$3.6Mheld
Hennion & Walsh Asset Management, Inc.3.4M$3.5Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC3.4M$3.5Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by OCGN insiders, by quarter · Form 4
-1.0M-500.0K0500.0K1.0M2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: 21.0K2026 Q22026 Q3: -526.0K2026 Q32026 Q4: -526.0K2026 Q4

Recent Insider Transactions

174 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Musunuri ShankarChief Executive Officer · Director Sale −57.3K $0.95 $54K Oct 9, 2026 Form 4 ↗
Musunuri ShankarChief Executive Officer · Director Sale −468.7K $0.95 $445K Oct 9, 2026 Form 4 ↗
Musunuri ShankarChief Executive Officer · Director Sale −57.3K $1.12 $64K Sep 9, 2026 Form 4 ↗
Musunuri ShankarChief Executive Officer · Director Sale −468.7K $1.12 $525K Sep 9, 2026 Form 4 ↗
Johnson-Greene Treerita EssalimaChief Financial Officer Purchase +21.0K $1.23 $26K Jun 15, 2026 Form 4 ↗
Zhang JungeDirector Option exercise +66.9K $1.42 $95K Apr 1, 2026 Form 4 ↗
Zhang JungeDirector Option exercise +112.2K $0.46 $52K Apr 1, 2026 Form 4 ↗
Zhang JungeDirector Option exercise +15.0K $0.51 $8K Apr 1, 2026 Form 4 ↗
Musunuri ShankarChief Executive Officer · Director Grant / award +3.1M $0.00 $0 Jan 2, 2026 Form 4 ↗
Ramachandran RameshChief Accounting Officer Grant / award +207.3K $0.00 $0 Jan 2, 2026 Form 4 ↗
Upadhyay ArunSee Remarks Tax withholding −41.6K $0.89 $37K Jan 3, 2025 Form 4 ↗
Musunuri ShankarChief Executive Officer · Director Tax withholding −177.1K $0.89 $158K Jan 3, 2025 Form 4 ↗
Fernandes PrabhavathiDirector Purchase +10.0K $0.91 $9K Nov 26, 2024 Form 4 ↗
Castillo KirstenDirector Purchase +25.0K $0.91 $23K Nov 22, 2024 Form 4 ↗
Upadhyay ArunSee Remarks Tax withholding −842 $1.17 $985 Sep 16, 2024 Form 4 ↗
Upadhyay ArunSee Remarks Tax withholding −917 $1.42 $1K Jun 17, 2024 Form 4 ↗
Musunuri ShankarChief Executive Officer · Director Tax withholding −180.2K $0.65 $117K Jan 3, 2024 Form 4 ↗
Upadhyay ArunSee Remarks Tax withholding −41.6K $0.65 $27K Jan 3, 2024 Form 4 ↗
Upadhyay ArunSee Remarks Tax withholding −842 $0.41 $345 Sep 16, 2023 Form 4 ↗
Upadhyay ArunChief Scientific Officer Tax withholding −917 $0.51 $468 Jun 16, 2023 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding OCGN · SEC Form N-PORT
FundSharesValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
14.0M$21.4M0.20%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
10.2M$15.6M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
8.7M$13.3M0.02%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
3.9M$5.9M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
3.7M$4.6M0.01%Jul 31, 2026
iShares Russell 2000 Growth ETF
iShares Trust
2.2M$3.4M0.02%Jun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF
SPDR SERIES TRUST
1.8M$2.8M0.10%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
2.0M$2.6M0.01%Aug 31, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
1.7M$2.2M0.01%Aug 31, 2026
iShares Micro-Cap ETF
iShares Trust
1.1M$1.8M0.12%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list OCGN's shares (CUSIP 67577C105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • JANUS HENDERSON GROUP Ltd.SCHEDULE 13G/A · passive (13G) · 10.0M shares3.0%
    Aug 13, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 21.5M shares6.3%
    Aug 7, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G · passive (13G) · 27.0M shares8.0%
    Jul 29, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming ocugen as client
$0$125K$250K$375K$500K2023 Q1: $50K2023 Q2: $60K2023 Q3: $90K2023 Q4: $60K20232024 Q1: $60K2024 Q2: $60K2024 Q3: $30K2024 Q4: $30K20242025 Q1: $30K2025 Q2: $30K2025 Q3: $30K2025 Q4: $30K20252026 Q1: $30K2026 Q2: $30K2026 Q3: $60K2026
  • RIDGE POLICY GROUPOCUGEN INC. · 2026 Q3 · HCR$30K
    Filing ↗
  • RIDGE POLICY GROUPOCUGEN INC. · 2026 Q3 · HCR$30K
    Filing ↗
  • RIDGE POLICY GROUPOCUGEN INC. · 2026 Q2 · HCR$30K
    Filing ↗
  • RIDGE POLICY GROUPOCUGEN INC. · 2026 Q1 · HCR$30K
    Filing ↗
  • RIDGE POLICY GROUPOCUGEN INC. · 2025 Q4 · HCR$30K
    Filing ↗

Government Contracts

Federal awards to Ocugen, Inc. · USAspending

No federal contract awards found for Ocugen, Inc..

U.S. Patents

Recent USPTO applications naming Ocugen, Inc.

No USPTO patent applications found for Ocugen, Inc..

Annual Financials

From OCGN's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$4.4M$4.1M$6.0M$2.5M$0
Operating income-$62.9M-$54.8M-$65.5M-$89.1M-$58.0M
Net income-$67.8M-$54.1M-$63.1M-$86.8M-$58.4M
Diluted EPSn/an/a-$0.26-$0.40-$0.30
Operating cash flow-$57.0M-$42.1M-$62.1M-$60.1M-$47.9M
Cash and equivalentsn/an/a$39.5M$77.6M$95.0M
Total assets$43.5M$82.4M$64.5M$108.6M$105.8M
Total liabilities$55.7M$52.8M$24.0M$34.7M$9.9M
Shareholders' equity-$12.2M$29.6M$40.6M$74.0M$91.2M

As Ocugen, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 4, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-60Reverse splitSep 30, 2019

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureNov 10, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsNov 4, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureOct 15, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 7.01, 8.01, 9.01Material agreement · Reg FD disclosure · Other eventsOct 15, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteOct 6, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteSep 23, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 8, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJul 13, 2026
    EDGAR ↗
  • 8-K · Items 5.07, 8.01Shareholder vote · Other eventsJun 11, 2026
    EDGAR ↗

About Ocugen, Inc.

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersMALVERN, PA
IncorporatedDE
Former namesHISTOGENICS CORP